This website uses cookies to ensure you have the best user experience. By continuing to use this website, you consent to our use of cookies. For more information, read our privacy policy.
BC200-Driven Translational Regulation as a Therapeutic Target and Biomarker in Tubo-Ovarian High-Grade Serous Carcinoma
In vivo modelling of chromosome instability in tubo-ovarian high grade serous carcinoma
Delving deeper into chaos of ovarian cancer genomes—from telomere-to-telomere
Testing the in vitro mechanism and in vivo efficacy of an experimental drug to kill epithelial ovarian cancer
Engaging Indigenous Communities to Understand Perspectives on Genetic Testing and Risk-Reducing Surgery for Ovarian Cancer in Alberta, Canada
Patient-centred Hereditary Ovarian Cancer Prevention and Survivorship Care in Canada
Metabolic engineering of CAR-T cells to overcome immune suppression
Understanding how glycosylated antitumour ether lipids (GAELs) kill chemotherapy-resistant cancer cells
Clonal hematopoiesis as a biomarker of poor prognosis in high-grade serous ovarian cancer
Implementation of patient-oriented Folate Receptor Alpha reporting
